Skip to main content
. 2024 Dec 2;24:3356. doi: 10.1186/s12889-024-20855-5

Table 2.

Comparison of baseline characteristics between PROMISE-EPI participants interviewed and non-interviewed, Lusaka, Zambia

PROMISE-EPI participants interviewed PROMISE-EPI participants not interviewed P value
N = 80a N = 1262
Intervention arm 49 (61.3%) 619 (49%) 0.038
Mothers
 Age mean (sd) 30.0 (6.5) 30.5 (5.9) 0.47
 Time of HIV diagnosis Before this last pregnancy 53 (66.3%) 899/1260 (71.3%) 0.37
During/after this last pregnancy 27 (33.8%) 361/1260 (28.7%)
Mothers taking ART 76 (95.0%) 1243 (98.5%) 0.044
 Highest level of education None 5 (6.3%) 82 (6.5%) 0.87
Primary 29 (36.3%) 494 (39.1%)
Secondary or more 46 (57.5%) 686 (54.4%)
 Employment situation during pregnancy Not working 56 (70.0%) 872 (69.1%) 0.61
Working (formal sector) 5 (6.3%) 122 (9.7%)
Working (informal sector) 17 (21.3%) 248 (19.7%)
Studying 2 (2.5%) 20 (1.6%)
 Marital status Married/cohabitating 63 (78.8%) 1,047 (83.0%) 0.43
Single 15 (18.8%) 173 (13.7%)
Divorced/separate/widowed 2 (2.5%) 42 (3.3%)
 HIV Status known by partner No 7/71 (9.9%) 88/974 (9.0%) 0.29
Yes 60/71 (84.5%) 858/974 (88.1%)
Not applicable (no partner) 4/71 (5.6%) 28/974 (2.9%)
 Maternal VL > = 1000cp/mL at EPI-2 (both arms) 38 (47.5%) 105/1222 (8.6%) < 0.001
 Maternal VL > = 1000cp/mL at M6 23/76 (30.3%) 64/1054 (6.1%) < 0.001
 Still breastfeeding at M12 63/79 (79.7%) 734/990 (74.1%) 0.35
Infants
 Sex Female 40 (50.0%) 611 (48.4%) 0.82
 Six week PNP at birth (3 drugs) 74 (92.5%) 1217/1262 (96.4%) 0.12
 Infant eligible to lamivudine at EPI-2 (intervention arm) 35 (43.8%) 37 (2.9%) < 0.001
 Newly eligible to lamivudine at M6 (mother on the intervention arm newly unsuppressed) 3 (3.8%) 13 (1.0%) 0.065

ART Antiretroviral therapy, VL Viral load, PNP Post-natal-prophylaxis, EPI-2 second visit of the expanded program on immunization

a The PROMISE-EPI identifier was not recorded for one PROMISE-EPI participant